Developer docs
API playgroundTry for free, no card

Search company profiles

Searchlight Pharma

Full company profile

uuid0005jlj

Namestring
Searchlight Pharma
Legal namestring
Searchlight Pharma Inc.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Searchlight Pharma is a Canadian specialty pharmaceutical company headquartered in Montreal, Quebec, that acquires, in-licenses, and commercializes branded pharmaceutical products across women's health, dermatology, pain management, neurology, allergy, and hospital specialty markets. Founded in 2015, the company built a portfolio of more than 65 branded products through a combination of organic launches, tuck-in acquisitions (notably Miravo Healthcare / Nuvo Pharmaceuticals in March 2023 and ERFA Canada 2012 in January 2022), and exclusive Canadian licensing agreements with international innovators including Grünenthal, Mithra Pharmaceuticals, Sol-Gel Technologies, Kissei Pharmaceutical, and Gedeon Richter. Its core technology approach is asset-light and centered on proprietary formulation platforms accessed through partnerships, exemplified by Sol-Gel's silica-based microencapsulation technology that underpins Twyneo (tretinoin + benzoyl peroxide for acne) and Epsolay (benzoyl peroxide for rosacea), both of which received FDA approval in the U.S. before being licensed into Canada.

Searchlight's revenue model blends branded product sales in Canada with licensing royalties and milestone payments from international partners. In Canada, products are commercialized through a flexible sales and marketing model targeting healthcare professionals and patients, distributed via pharmacy, hospital, and specialty channels. Internationally, the company monetizes Canadian-originated or owned intellectual property through outbound licensing (e.g., Suvexx licensed to Orion Corporation for all EU markets) and captures upfront fees, regulatory and sales milestones, and tiered royalties from inbound partners. Key revenue drivers include established women's health brands (Nextstellis, Evra, Haloette, Mona Lisa IUDs), dermatology assets (Epsolay), migraine therapy (Suvexx), and a late-stage pipeline anchored by DONESTA (menopause), Qutenza (neuropathic pain), Nebido (testosterone replacement), and linzagolix (uterine fibroids).

In June 2024, Apotex Inc., Canada's largest pharmaceutical company, completed the acquisition of Searchlight Pharma, which now operates as Apotex's Branded Medicines Division. The combination pairs Searchlight's specialty and innovative branded portfolio with Apotex's leadership in generic and biosimilar pharmaceuticals, distribution scale, and manufacturing capabilities (including the Varennes, Quebec production facility). The company has earned Globe and Mail Top Growing Companies recognition for five consecutive years (2019-2023), Miravo Healthcare (now a subsidiary) received the Globe and Mail Women Lead Here award for three consecutive years (2021-2023), and the combined entity maintains commercial operations across Canada with international operations through its Dublin-based Nuvo Ireland subsidiary.

Short descriptiontext

Searchlight Pharma is Apotex's Branded Medicines Division, a Canadian specialty pharmaceutical company that in-licenses, develops, and commercializes branded prescription products across women's health, dermatology, pain, neurology, allergy, and hospital specialty markets for Canadian healthcare professionals and patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, branded medicines, women's health therapeutics, dermatology products, pharmaceutical commercialization
Industry4 codes
PRIMARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Branded Product Sales
TypeLicensing Royalties
Description

Searchlight Pharma generates revenue through the sale and commercialization of its portfolio of branded specialty pharmaceutical products in Canada, including women's health, dermatology, allergy, neurology, pain management, and hospital specialty products. The company holds exclusive commercial and marketing rights for these products in Canada.

searchlightpharma.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

As Apotex's branded medicines division, Searchlight enters into licensing agreements where partners receive upfront payments, regulatory milestone payments, and sales-based royalties. For example, the DONESTA agreement includes €1.5M upfront and up to €15.55M in regulatory and sales milestones plus royalties. Sol-Gel agreements include up to $11M in milestones plus 10-19% royalties on net sales.

searchlightpharma.com
3International Licensing (Suvexx)
TypeLicensing Royalties
Description

Searchlight's subsidiary Nuvo Ireland holds intellectual property rights for Suvexx outside Canada. Orion Corporation launched Suvexx in Europe under a license and supply agreement, with upfront payments (€600K), launch payments (€400K), sales milestones, and royalties flowing back to Searchlight/Nuvo Ireland.

searchlightpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Marketing or Sales, Operations, Supply Chain, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Searchlight Pharma is a Canadian specialty pharmaceutical company that acquires, in-licenses, and commercializes branded healthcare products in Canada. Its portfolio spans women's health (contraception, menopause, uterine fibroids), dermatology, allergy, neurology, pain management, and hospital specialty markets, totaling 65+ brands. The company holds exclusive Canadian commercial rights to products from international partners such as Grünenthal, Mithra, Kissei, and Sol-Gel.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Ranked among top 3 specialty pharmaceutical companies in Canada (post-Miravo acquisition)
+3 more records
Product overview1 text field

Searchlight Pharma is Apotex's Branded Medicines Division, operating as a specialty pharmaceutical company focused on acquiring and commercializing innovative healthcare products. The portfolio includes over 65 brands across key therapeutic areas including women's health (contraceptives like Nextstellis, Evra, Haloette, and IUDs; hormone therapies like Divigel and Estragyn), dermatology (Epsolay, Twyneo), allergy (Blexten, Atarax), pain management (Suvexx, Cambia, Ketalar), neurology (Valium, Nardil, Zarontin), and hospital specialty markets. The company operates a commercial brands portfolio of marketed products alongside a pipeline of products awaiting regulatory approval (including DONESTA for menopause and Twyneo for acne), and manages partnered brands distributed through international licensing agreements (including Suvexx in Europe with Orion Corporation, Pennsaid, Treximet, and Vimovo). Searchlight also holds exclusive Canadian licensing rights to several products from partners including Grünenthal (Nebido, Qutenza), Kissei Pharmaceutical (linzagolix), Mithra (DONESTA), and Sol-Gel (Twyneo, Epsolay).

Product and service2 records
1Nextstellis
CategoryWomen's Health - Contraception
Description

Combined oral contraceptive containing estetrol monohydrate and drospirenone, the first contraceptive approved globally based on estetrol (E4). For women seeking contraception.

2Evra
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership19 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-02-05
Description

Apotex's Searchlight Pharma division signed an exclusive licensing agreement with Grünenthal to market Nebido (testosterone undecanoate), a long-acting injectable therapy for male hypogonadism, in Canada. Searchlight will pursue regulatory approval and market and distribute the product upon authorization. Grünenthal receives upfront payment, regulatory milestone payments, and a margin on sales. This marks Apotex's first entry into testosterone therapy and deepens an existing partnership, which also includes Qutenza (neuropathic pain patch).

2Kissei Pharmaceutical
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-10-07
Description

Searchlight Pharma entered into a licensing agreement securing exclusive Canadian rights to linzagolix, an oral GnRH antagonist treatment for uterine fibroids developed by Japan's Kissei Pharmaceutical. The product is marketed as Yselty in Europe. Searchlight will lead regulatory efforts to pursue marketing authorization in Canada, where uterine fibroids affect up to 70% of women by age 50.

prnewswire.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-02-24
Description

Apotex and Grünenthal signed a strategic licensing agreement granting Apotex exclusive Canadian rights to Qutenza, a topical non-systemic, non-opioid pain patch for neuropathic pain management. Searchlight Pharma will pursue regulatory approval and market the product in Canada, with Grünenthal receiving upfront, regulatory milestone, and royalty payments.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-26
Description

Mithra and Searchlight Pharma signed a licensing and supply agreement for Canadian rights to DONESTA, a next-generation oral hormone therapy based on estetrol for menopause symptoms. Mithra receives €1.5M upfront, up to €15.55M in regulatory and sales milestones, and tiered double-digit royalties on net sales. Searchlight will file for Canadian regulatory approval in H1 2024. This is the third licensing agreement between the companies, following NEXTSTELLIS (launched Q3 2021) and HALOETTE (launched Q1 2022).

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-08-15
Description

Orion Corporation launched Suvexx (sumatriptan/naproxen sodium) in Europe under a license and supply agreement with Searchlight's subsidiary Nuvo Ireland. An amendment extended the agreement to all EU markets. Orion received an upfront payment of €600K and will pay €400K upon launch in significant EU markets, plus sales milestones and royalties. Orion is responsible for obtaining and maintaining marketing authorizations and managing commercial activities across European territories.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-06-06
Description

Sol-Gel and Searchlight signed exclusive license agreements for TWYNEO (tretinoin + benzoyl peroxide cream for acne) and EPSOLAY (benzoyl peroxide 5% cream for rosacea) for the Canadian market. Sol-Gel could receive up to $11M in milestone payments tied to regulatory and sales achievements, plus royalties of 10-19% on net Canadian sales. The 15-year renewable agreements position both products as foundational elements of Searchlight's dermatology pipeline and portfolio.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-05-12
Description

Gedeon Richter and Searchlight Pharma announced Searchlight's assumption of all Canadian distribution and promotion activities for Evra, a transdermal contraceptive patch. The transition resulted from Richter's acquisition of Evra rights from Janssen Pharmaceutica (J&J) in December 2020. Evra generated CAD $12 million in sales in Canada in 2021 and remains the only transdermal contraceptive option available in Canada (approved by Health Canada since 2002).

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Gebro Pharma AG (Switzerland) is a partner for the distribution of Pennsaid 2% and Pennsaid in their respective territories.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Paladin Labs (Canada) is a partnered brand distributor for Pennsaid in Canada.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Vianex S.A. (Greece) is a partnered brand distributor.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Recordati S.p.A. (Italy) is a partnered brand distributor.

12Fagron Belgium NV
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Fagron Belgium NV (Benelux) is a partnered brand distributor for Resultz.

searchlightpharma.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Heumann Pharma GmbH & Co. Generica KG (Germany) is a partnered brand distributor for Lausbub.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Reckitt Benckiser (UK, Ireland, Russia, Spain, Portugal) is a partnered brand distributor for FullMarks.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

SK Chemicals Co., Ltd. (South Korea) is a partnered brand distributor for Suvexx.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Currax Holdings USA LLC (USA) is a partnered brand distributor for Treximet (the US brand name for Suvexx).

17Horizon Therapeutics plc
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Horizon Therapeutics plc (USA) is a partnered brand distributor for Vimovo.

searchlightpharma.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Grünenthal GmbH (ROW) is a partnered brand distributor.

Strategic tierCoreTypeOthers
Description

Apotex Inc. completed the acquisition of Searchlight Pharma in June 2024. Searchlight operates as Apotex's Branded Medicines Division, combining Searchlight's strong specialty and innovative branded product portfolio with Apotex's market leadership in generic and biosimilar pharmaceuticals.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Canadian specialty pharmaceutical company that in-licenses and commercializes innovative products across women's health, oncology, and specialty therapeutics in Canada and select international markets. Directly comparable business model and target customer base to Searchlight.

TypeBroad incumbent
Description

Global women's health-focused pharmaceutical company spun out from Merck, with established franchises in contraception, fertility, and menopause. A larger incumbent operating in the same therapeutic categories that Searchlight targets.

3Endo International
TypeBroad incumbent
Description

Global specialty pharmaceutical company with a portfolio spanning branded specialty, generics, and sterile injectables. Owns Paladin Labs and competes in overlapping dermatology, pain, and women's health categories with Searchlight's portfolio.

TypeDirect peer
Description

Canadian specialty pharma focused on acquiring and commercializing branded products in CNS, cardiology, and women's health. Operates with a similar in-licensing model targeting Canadian healthcare professionals, making it a directly comparable peer.

TypeBroad incumbent
Description

Hungarian-headquartered specialty pharmaceutical company with a strong women's health portfolio including Evra (rights acquired from J&J). Searchlight partners with Richter for Evra distribution in Canada, and Richter competes in overlapping women's health categories.

TypeDirect peer
Description

Global specialty pharmaceutical company exclusively focused on women's health, with a portfolio spanning contraception, menopause, and fertility. Direct strategic overlap with Searchlight's primary women's health focus and similar in-licensing model.

TypeBroad incumbent
Description

Large diversified pharmaceutical company with a major Canadian commercial presence across dermatology, neurology, and specialty brands. Operates as a broad incumbent with overlapping therapeutic categories and Canadian market overlap.

TypeDirect peer
Description

Canadian specialty pharma (acquired by Endo International) that acquires, in-licenses, and markets branded prescription products. Adam Bulow, Searchlight's VP, spent 10 years at Paladin, and the company is a partnered brand distributor for Searchlight's Pennsaid in Canada.

9Acerus Pharmaceuticals
TypeDirect peer
Description

Canadian specialty pharmaceutical company focused on men's health (testosterone replacement) and women's health, with a similar lean operating model and Canadian commercialization footprint. Recently acquired by Aytu BioPharma.

TypeDirect peer
Description

Canadian specialty pharmaceutical company focused on commercializing specialty products in dermatology and hospital specialty markets. Similar in-licensing and commercialization approach, and overlapping therapeutic areas with Searchlight.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Searchlight Pharma

Specialty Pharmaceuticalssearchlightpharma.com

Searchlight Pharma is Apotex's Branded Medicines Division, a Canadian specialty pharmaceutical company that in-licenses, develops, and commercializes branded prescription products across women's health, dermatology, pain, neurology, allergy, and hospital specialty markets for Canadian healthcare professionals and patients.

What Searchlight Pharma does

Searchlight Pharma is a Canadian specialty pharmaceutical company headquartered in Montreal, Quebec, that acquires, in-licenses, and commercializes branded pharmaceutical products across women's health, dermatology, pain management, neurology, allergy, and hospital specialty markets. Founded in 2015, the company built a portfolio of more than 65 branded products through a combination of organic launches, tuck-in acquisitions (notably Miravo Healthcare / Nuvo Pharmaceuticals in March 2023 and ERFA Canada 2012 in January 2022), and exclusive Canadian licensing agreements with international innovators including Grünenthal, Mithra Pharmaceuticals, Sol-Gel Technologies, Kissei Pharmaceutical, and Gedeon Richter. Its core technology approach is asset-light and centered on proprietary formulation platforms accessed through partnerships, exemplified by Sol-Gel's silica-based microencapsulation technology that underpins Twyneo (tretinoin + benzoyl peroxide for acne) and Epsolay (benzoyl peroxide for rosacea), both of which received FDA approval in the U.S. before being licensed into Canada.

Searchlight's revenue model blends branded product sales in Canada with licensing royalties and milestone payments from international partners. In Canada, products are commercialized through a flexible sales and marketing model targeting healthcare professionals and patients, distributed via pharmacy, hospital, and specialty channels. Internationally, the company monetizes Canadian-originated or owned intellectual property through outbound licensing (e.g., Suvexx licensed to Orion Corporation for all EU markets) and captures upfront fees, regulatory and sales milestones, and tiered royalties from inbound partners. Key revenue drivers include established women's health brands (Nextstellis, Evra, Haloette, Mona Lisa IUDs), dermatology assets (Epsolay), migraine therapy (Suvexx), and a late-stage pipeline anchored by DONESTA (menopause), Qutenza (neuropathic pain), Nebido (testosterone replacement), and linzagolix (uterine fibroids).

In June 2024, Apotex Inc., Canada's largest pharmaceutical company, completed the acquisition of Searchlight Pharma, which now operates as Apotex's Branded Medicines Division. The combination pairs Searchlight's specialty and innovative branded portfolio with Apotex's leadership in generic and biosimilar pharmaceuticals, distribution scale, and manufacturing capabilities (including the Varennes, Quebec production facility). The company has earned Globe and Mail Top Growing Companies recognition for five consecutive years (2019-2023), Miravo Healthcare (now a subsidiary) received the Globe and Mail Women Lead Here award for three consecutive years (2021-2023), and the combined entity maintains commercial operations across Canada with international operations through its Dublin-based Nuvo Ireland subsidiary.

Searchlight Pharma firmographics

Firmographics
Name
Searchlight Pharma
Legal name
Searchlight Pharma Inc.
Website
https://searchlightpharma.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Searchlight Pharma is Apotex's Branded Medicines Division, a Canadian specialty pharmaceutical company that in-licenses, develops, and commercializes branded prescription products across women's health, dermatology, pain, neurology, allergy, and hospital specialty markets for Canadian healthcare professionals and patients.
Ownership category
akta.pro rank

Searchlight Pharma industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Branded medicines
  • Women's health therapeutics
  • Dermatology products
  • Pharmaceutical commercialization

Where Searchlight Pharma is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Offices4 records

Markets served

Searchlight Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Marketing or Sales, Operations, Supply Chain, Technology or R&D, Others

Revenue model

  1. Branded Product Sales: Searchlight Pharma generates revenue through the sale and commercialization of its portfolio of branded specialty pharmaceutical products in Canada, including women's health, dermatology, allergy, neurology, pain management, and hospital specialty products. The company holds exclusive commercial and marketing rights for these products in Canada.
  2. Licensing and Milestone Payments: As Apotex's branded medicines division, Searchlight enters into licensing agreements where partners receive upfront payments, regulatory milestone payments, and sales-based royalties. For example, the DONESTA agreement includes €1.5M upfront and up to €15.55M in regulatory and sales milestones plus royalties. Sol-Gel agreements include up to $11M in milestones plus 10-19% royalties on net sales.
  3. International Licensing (Suvexx): Searchlight's subsidiary Nuvo Ireland holds intellectual property rights for Suvexx outside Canada. Orion Corporation launched Suvexx in Europe under a license and supply agreement, with upfront payments (€600K), launch payments (€400K), sales milestones, and royalties flowing back to Searchlight/Nuvo Ireland.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Searchlight Pharma product offering

Product offering

Core offering

Searchlight Pharma is a Canadian specialty pharmaceutical company that acquires, in-licenses, and commercializes branded healthcare products in Canada. Its portfolio spans women's health (contraception, menopause, uterine fibroids), dermatology, allergy, neurology, pain management, and hospital specialty markets, totaling 65+ brands. The company holds exclusive Canadian commercial rights to products from international partners such as Grünenthal, Mithra, Kissei, and Sol-Gel.

Product overview

Searchlight Pharma is Apotex's Branded Medicines Division, operating as a specialty pharmaceutical company focused on acquiring and commercializing innovative healthcare products. The portfolio includes over 65 brands across key therapeutic areas including women's health (contraceptives like Nextstellis, Evra, Haloette, and IUDs; hormone therapies like Divigel and Estragyn), dermatology (Epsolay, Twyneo), allergy (Blexten, Atarax), pain management (Suvexx, Cambia, Ketalar), neurology (Valium, Nardil, Zarontin), and hospital specialty markets. The company operates a commercial brands portfolio of marketed products alongside a pipeline of products awaiting regulatory approval (including DONESTA for menopause and Twyneo for acne), and manages partnered brands distributed through international licensing agreements (including Suvexx in Europe with Orion Corporation, Pennsaid, Treximet, and Vimovo). Searchlight also holds exclusive Canadian licensing rights to several products from partners including Grünenthal (Nebido, Qutenza), Kissei Pharmaceutical (linzagolix), Mithra (DONESTA), and Sol-Gel (Twyneo, Epsolay).

Differentiator

Problem solved

Functional benefit

Products and services

  • Nextstellis Combined oral contraceptive containing estetrol monohydrate and drospirenone, the first contraceptive approved globally based on estetrol (E4). For women seeking contraception.
  • Evra

Quantifiable outcome

  • Ranked among top 3 specialty pharmaceutical companies in Canada (post-Miravo acquisition)
  • +3 more outcomes

Companies that use Searchlight Pharma

Customer profile

Segments4 records

Ideal customer profiles2 records

Searchlight Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Searchlight Pharma partnerships and signals

Strategic signal

Partnerships

19 partnerships are on record, tiered core and minor.

  • GrünenthalcoreOEM/ Whitelabel/ Licensing Partner · 5 February 2026Apotex's Searchlight Pharma division signed an exclusive licensing agreement with Grünenthal to market Nebido (testosterone undecanoate), a long-acting injectable therapy for male hypogonadism, in Canada. Searchlight will pursue regulatory approval and market and distribute the product upon authorization. Grünenthal receives upfront payment, regulatory milestone payments, and a margin on sales. This marks Apotex's first entry into testosterone therapy and deepens an existing partnership, which also includes Qutenza (neuropathic pain patch).
  • Kissei PharmaceuticalcoreOEM/ Whitelabel/ Licensing Partner · 7 October 2025Searchlight Pharma entered into a licensing agreement securing exclusive Canadian rights to linzagolix, an oral GnRH antagonist treatment for uterine fibroids developed by Japan's Kissei Pharmaceutical. The product is marketed as Yselty in Europe. Searchlight will lead regulatory efforts to pursue marketing authorization in Canada, where uterine fibroids affect up to 70% of women by age 50.
  • GrünenthalcoreOEM/ Whitelabel/ Licensing Partner · 24 February 2025Apotex and Grünenthal signed a strategic licensing agreement granting Apotex exclusive Canadian rights to Qutenza, a topical non-systemic, non-opioid pain patch for neuropathic pain management. Searchlight Pharma will pursue regulatory approval and market the product in Canada, with Grünenthal receiving upfront, regulatory milestone, and royalty payments.
  • Mithra PharmaceuticalscoreStrategic or Co-development Partner · 26 October 2023Mithra and Searchlight Pharma signed a licensing and supply agreement for Canadian rights to DONESTA, a next-generation oral hormone therapy based on estetrol for menopause symptoms. Mithra receives €1.5M upfront, up to €15.55M in regulatory and sales milestones, and tiered double-digit royalties on net sales. Searchlight will file for Canadian regulatory approval in H1 2024. This is the third licensing agreement between the companies, following NEXTSTELLIS (launched Q3 2021) and HALOETTE (launched Q1 2022).
  • Orion CorporationcoreChannel Partner/ Reseller/ Distributor · 15 August 2023Orion Corporation launched Suvexx (sumatriptan/naproxen sodium) in Europe under a license and supply agreement with Searchlight's subsidiary Nuvo Ireland. An amendment extended the agreement to all EU markets. Orion received an upfront payment of €600K and will pay €400K upon launch in significant EU markets, plus sales milestones and royalties. Orion is responsible for obtaining and maintaining marketing authorizations and managing commercial activities across European territories.
  • Sol-Gel TechnologiescoreOEM/ Whitelabel/ Licensing Partner · 6 June 2023Sol-Gel and Searchlight signed exclusive license agreements for TWYNEO (tretinoin + benzoyl peroxide cream for acne) and EPSOLAY (benzoyl peroxide 5% cream for rosacea) for the Canadian market. Sol-Gel could receive up to $11M in milestone payments tied to regulatory and sales achievements, plus royalties of 10-19% on net Canadian sales. The 15-year renewable agreements position both products as foundational elements of Searchlight's dermatology pipeline and portfolio.
  • Gedeon RichtercoreChannel Partner/ Reseller/ Distributor · 12 May 2022Gedeon Richter and Searchlight Pharma announced Searchlight's assumption of all Canadian distribution and promotion activities for Evra, a transdermal contraceptive patch. The transition resulted from Richter's acquisition of Evra rights from Janssen Pharmaceutica (J&J) in December 2020. Evra generated CAD $12 million in sales in Canada in 2021 and remains the only transdermal contraceptive option available in Canada (approved by Health Canada since 2002).
  • Gebro Pharma AGminorChannel Partner/ Reseller/ DistributorGebro Pharma AG (Switzerland) is a partner for the distribution of Pennsaid 2% and Pennsaid in their respective territories.
  • Paladin LabsminorChannel Partner/ Reseller/ DistributorPaladin Labs (Canada) is a partnered brand distributor for Pennsaid in Canada.
  • Vianex S.A.minorChannel Partner/ Reseller/ DistributorVianex S.A. (Greece) is a partnered brand distributor.
  • Recordati S.p.A.minorChannel Partner/ Reseller/ DistributorRecordati S.p.A. (Italy) is a partnered brand distributor.
  • Fagron Belgium NVminorChannel Partner/ Reseller/ DistributorFagron Belgium NV (Benelux) is a partnered brand distributor for Resultz.
  • Heumann Pharma GmbH & Co. Generica KGminorChannel Partner/ Reseller/ DistributorHeumann Pharma GmbH & Co. Generica KG (Germany) is a partnered brand distributor for Lausbub.
  • Reckitt Benckiser (Brands) LimitedminorChannel Partner/ Reseller/ DistributorReckitt Benckiser (UK, Ireland, Russia, Spain, Portugal) is a partnered brand distributor for FullMarks.
  • SK Chemicals Co., Ltd.minorChannel Partner/ Reseller/ DistributorSK Chemicals Co., Ltd. (South Korea) is a partnered brand distributor for Suvexx.
  • Currax Holdings USA LLCminorChannel Partner/ Reseller/ DistributorCurrax Holdings USA LLC (USA) is a partnered brand distributor for Treximet (the US brand name for Suvexx).
  • Horizon Therapeutics plcminorChannel Partner/ Reseller/ DistributorHorizon Therapeutics plc (USA) is a partnered brand distributor for Vimovo.
  • Grünenthal GmbH (ROW)minorChannel Partner/ Reseller/ DistributorGrünenthal GmbH (ROW) is a partnered brand distributor.
  • Apotex Inc.coreOthersApotex Inc. completed the acquisition of Searchlight Pharma in June 2024. Searchlight operates as Apotex's Branded Medicines Division, combining Searchlight's strong specialty and innovative branded product portfolio with Apotex's market leadership in generic and biosimilar pharmaceuticals.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Searchlight Pharma competitors and assessment

Company assessment

Direct peers

  • Knight Therapeutics: Canadian specialty pharmaceutical company that in-licenses and commercializes innovative products across women's health, oncology, and specialty therapeutics in Canada and select international markets. Directly comparable business model and target customer base to Searchlight.
  • HLS Therapeutics: Canadian specialty pharma focused on acquiring and commercializing branded products in CNS, cardiology, and women's health. Operates with a similar in-licensing model targeting Canadian healthcare professionals, making it a directly comparable peer.
  • Theramex: Global specialty pharmaceutical company exclusively focused on women's health, with a portfolio spanning contraception, menopause, and fertility. Direct strategic overlap with Searchlight's primary women's health focus and similar in-licensing model.
  • Paladin Labs: Canadian specialty pharma (acquired by Endo International) that acquires, in-licenses, and markets branded prescription products. Adam Bulow, Searchlight's VP, spent 10 years at Paladin, and the company is a partnered brand distributor for Searchlight's Pennsaid in Canada.
  • Acerus Pharmaceuticals: Canadian specialty pharmaceutical company focused on men's health (testosterone replacement) and women's health, with a similar lean operating model and Canadian commercialization footprint. Recently acquired by Aytu BioPharma.
  • Cipher Pharmaceuticals: Canadian specialty pharmaceutical company focused on commercializing specialty products in dermatology and hospital specialty markets. Similar in-licensing and commercialization approach, and overlapping therapeutic areas with Searchlight.

Broad incumbents

  • Organon: Global women's health-focused pharmaceutical company spun out from Merck, with established franchises in contraception, fertility, and menopause. A larger incumbent operating in the same therapeutic categories that Searchlight targets.
  • Endo International: Global specialty pharmaceutical company with a portfolio spanning branded specialty, generics, and sterile injectables. Owns Paladin Labs and competes in overlapping dermatology, pain, and women's health categories with Searchlight's portfolio.
  • Gedeon Richter: Hungarian-headquartered specialty pharmaceutical company with a strong women's health portfolio including Evra (rights acquired from J&J). Searchlight partners with Richter for Evra distribution in Canada, and Richter competes in overlapping women's health categories.
  • Bausch Health: Large diversified pharmaceutical company with a major Canadian commercial presence across dermatology, neurology, and specialty brands. Operates as a broad incumbent with overlapping therapeutic categories and Canadian market overlap.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Searchlight Pharma compliance and trust

Trust signal

Compliance3 records

Searchlight Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Searchlight Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Searchlight Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Searchlight Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Searchlight Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Searchlight Pharma

What does Searchlight Pharma do?

Searchlight Pharma is a Canadian specialty pharmaceutical company that acquires, in-licenses, and commercializes branded healthcare products in Canada. Its portfolio spans women's health (contraception, menopause, uterine fibroids), dermatology, allergy, neurology, pain management, and hospital specialty markets, totaling 65+ brands. The company holds exclusive Canadian commercial rights to products from international partners such as Grünenthal, Mithra, Kissei, and Sol-Gel.

Is Searchlight Pharma a public or private company?

Searchlight Pharma is a private company. It is classified as corporate owned and is currently operating.

When was Searchlight Pharma founded?

Searchlight Pharma was founded in 2018. It employs 11 to 50 people.

Where is Searchlight Pharma based?

Searchlight Pharma is headquartered in Montreal, Canada, in the North America region.

How does Searchlight Pharma make money?

Three revenue lines are on record. Branded Product Sales are the primary driver. The others are licensing and Milestone Payments and international Licensing (Suvexx).

Who are Searchlight Pharma's main competitors?

Direct peers on record are Knight Therapeutics, HLS Therapeutics, Theramex, Paladin Labs, Acerus Pharmaceuticals and Cipher Pharmaceuticals. Broad incumbents are Organon, Endo International, Gedeon Richter and Bausch Health.

Does Searchlight Pharma have an API?

No public API is recorded for Searchlight Pharma.

What industry is Searchlight Pharma in?

Searchlight Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAN, Women’s Health & Reproductive Specialty Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Globe and MailApotex expected to fetch $10-billion valuation as drugmaker files to go public on TSXApotex Health Corp. filed to go public on the Toronto Stock Exchange, expecting to raise $500 million to $1 billion. The company, Canada's largest generic drugmaker, could achieve an equity valuation exceeding $10 billion. Proceeds will repay indebtedness from a prior recapitalization.Mexico Business NewsCanadian Pharmaceutical Company Reinforces Mexico StrategyCanadian pharmaceutical company Apotex is reinforcing its commitment to Mexico, projecting an economic impact of MX$850 million (approximately US$50 million) this year while preparing to surpass 74 million units produced annually at its finished-dosage facility in Iztacalco, marking the highest output in the plant's nearly 30-year history. The company announced additional planned investment for fiscal year 2027 to further expand Mexico's capacity for manufacturing internationally certified generic medicines, reinforcing regional supply resilience. Separately, Apotex's Searchlight Pharma division signed an exclusive licensing agreement with Grünenthal to market Nebido, a long-acting testosterone replacement therapy, in Canada.GlobeNewswireSol-Gel Announces Health Canada Approval of EPSOLAY®Health Canada approved EPSOLAY for rosacea treatment on August 27, 2025, under a Searchlight Pharma license. Sol-Gel is eligible for up to $11 million in milestone payments and tiered royalties. The company expects ex-U.S. launches in 2027-2028, with potential $10 million annual EBITDA by 2031.BioSpaceApotex Completes Acquisition of Searchlight, a leading Canadian-based Specialty Innovative Branded Pharmaceutical CompanyApotex Inc. has completed its acquisition of Searchlight Pharma Inc., a Canadian specialty pharmaceutical company, integrating it as the new Specialty Pharma Division under Apotex. This strategic move is intended to accelerate Apotex's growth in the innovative branded pharmaceutical market and diversify its portfolio beyond generic medicines.NewswireApotex Completes Acquisition of Searchlight, a leading Canadian-based Specialty Innovative Branded Pharmaceutical CompanyApotex Inc. has completed the acquisition of Searchlight Pharma Inc., a Canadian specialty innovative branded pharmaceutical company, integrating it as the new Specialty Pharma Division under Apotex. This strategic move is designed to accelerate Apotex's growth in the specialty market and diversify its portfolio beyond traditional generic pharmaceuticals.ThemiddlemarketPE-Backed Apotex Purchases Searchlight PharmaApotex Inc., a Canadian pharmaceutical company backed by SK Capital, has agreed to acquire Searchlight Pharma to expand its portfolio into the branded pharmaceutical market. The transaction adds over 60 products and a commercialization platform to Apotex's existing generic and biosimilar business.PR NewswireApotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical LeaderApotex Inc. has reached an agreement to acquire Searchlight Pharma, a Canadian specialty branded pharmaceutical company, in a transaction expected to close in the second quarter of 2024. The acquisition adds over 60 products and a full-service platform to Apotex, accelerating its expansion into the high-value innovative branded pharmaceuticals sector across the Americas. Following the deal, Searchlight will operate as a division of Apotex with its headquarters remaining in Montreal.The Globe and MailApotex buys specialty pharma Searchlight in $500-million-plus move to diversify from generic drugsApotex Inc. has acquired fast-growing specialty pharmaceutical supplier Searchlight Pharma Inc. in a transaction valued at more than $500 million, marking a strategic shift to diversify beyond generic drugs. This acquisition adds a growth driver to Apotex's portfolio ahead of its anticipated initial public offering, leveraging Searchlight’s patented drug distribution network.IndianpharmapostApotex to acquire Canadian Searchlight PharmaApotex has announced an agreement to acquire Canadian specialty pharmaceutical company Searchlight Pharma, with the transaction expected to close in the second quarter of 2024 subject to regulatory conditions. This acquisition is described by Apotex as a strategic move to expand into the high-value innovative branded pharmaceuticals sector, complementing its existing position in generics and biosimilars.GlobeNewswireLetter to Shareholders and Corporate UpdateMithra Pharmaceuticals CEO Dr. David Horn Solomon reported significant strategic progress, including raising EUR 20 million in equity financing and securing a supply agreement with Gedeon Richter to improve manufacturing costs. The company also finalized a licensing deal with Searchlight Pharma for Donesta in Canada and received a milestone payment from Fuji Pharma for Estelle's development in Japan.